1 1 SMC2179 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life process abemaciclib (Verzenios®) is accepted for restricted use within NHSScotland. Indication under review: For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy or in women who have received prior endocrine therapy. SMC restriction: for use in women who have progressed on or after (neo) adjuvant endocrine therapy, or progressed during first-line endocrine-based therapy for advanced breast cancer In a phase III randomised study in women with HR-positive, HER2-negative advanced breast cancer who had received prior endocrine therapy, abemaciclib in combination with fulvestrant significantly increased progression-free survival compared with endocrine monotherapy. This SMC advice takes account of the benefit of Patient Access Schemes (PAS) that improve the cost effectiveness of abemaciclib and fulvestrant. This advice is contingent upon the continuing availability of these PAS in NHSScotland or list prices that are equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting. * For SMC advice relating to the use of abemaciclib in combination with an aromatase inhibitor in this setting, please refer to SMC2135. Chairman, Scottish Medicines Consortium www.scottishmedicines.org.uk
14
Embed
abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®)€¦ · Antidiarrhoeals were required for the majority of patients treated with abemaciclib.4 Summary of clinical effectiveness
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
1
SMC2179
abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company
5 April 2019
The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:
ADVICE: following a full submission assessed under the end of life process abemaciclib (Verzenios®) is accepted for restricted use within NHSScotland. Indication under review: For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy or in women who have received prior endocrine therapy. SMC restriction: for use in women who have progressed on or after (neo) adjuvant endocrine therapy, or progressed during first-line endocrine-based therapy for advanced breast cancer In a phase III randomised study in women with HR-positive, HER2-negative advanced breast cancer who had received prior endocrine therapy, abemaciclib in combination with fulvestrant significantly increased progression-free survival compared with endocrine monotherapy. This SMC advice takes account of the benefit of Patient Access Schemes (PAS) that improve the cost effectiveness of abemaciclib and fulvestrant. This advice is contingent upon the continuing availability of these PAS in NHSScotland or list prices that are equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting. * For SMC advice relating to the use of abemaciclib in combination with an aromatase inhibitor in this setting, please refer to SMC2135.
Chairman, Scottish Medicines Consortium
www.scottishmedicines.org.uk
2
Indication For the treatment of women with hormone receptor (HR) positive, human epidermal growth
factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination
with fulvestrant as initial endocrine-based therapy or in women who have received prior
endocrine therapy.
Dosing Information The recommended dose of abemaciclib is 150mg twice daily when used in combination with
endocrine therapy. Please refer to the Summary of Product Characteristics of the endocrine
therapy combination partner for the recommended posology.
In pre- or peri-menopausal women, the endocrine therapy should be combined with a
tamoxifen, or fulvestrant. The guideline suggests that there is some uncertainty around the
optimal role of the CDK inhibitors - palbociclib, ribociclib and abemaciclib, in clinical practice.5
Additional information: comparators
Fulvestrant and everolimus plus exemestane are considered the predominant comparators but
exemestane and tamoxifen may also be considered as lesser comparators in this setting
Cost of relevant comparators
Medicine Dose Regimen Cost per year (£)
abemaciclib plus
fulvestrant
abemaciclib 150mg oral twice
daily plus fulvestrant 500mg
intramuscular every 2 weeks
for the first 3 doses, then
500mg every month
45,664
fulvestrant 500mg intramuscular every 2
weeks for the first 3 doses,
then 500mg every month
7,314
everolimus plus
exemestane
everolimus 10mg oral once
daily plus exemestane 25mg
oral once daily
34,855
exemestane 25mg oral once daily. 106
tamoxifen 20mg oral once daily 34
Doses are for general comparison and do not imply therapeutic equivalence. Costs from BNF online
(abemaciclib cost from MIMs online) on 14 January 2019. Costs do not take any patient access
schemes into consideration. Regimens assume maximum licensed dose for the indication is
tolerated.
12
Additional information: budget impact
The company estimated there would be 492 patients eligible for treatment each year to which
confidential uptake rates were applied.
SMC is unable to publish the with PAS budget impact due to commercial in confidence issues. A
budget impact template is provided in confidence to NHS health boards to enable them to
estimate the predicted budget with the PAS.
Other data were also assessed but remain confidential.*
13
References
1. Eli Lilly and Company. Summary of product characteristics. Verzenios(r). 2018 [cited 2018 Oct 09]; Available from: https://www.medicines.org.uk/emc/product/9532. 2. Sledge GW, Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-84. Epub 06/06. 3. European Medicines Agency. abemaciclib (Verzenios) European Public Assessment Report. Procedure No. EMEA/H/C/004302/0000. 2018 26 July 2018. Report No. 4. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-46. Epub 10/03. 5. Cardoso F SE, Costa A, Papadopoulos E, et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology. 2018;29(8):1634-57. 6. National Institute for Health and Care Excellence. Clinical Guideline 81. Advanced breast cancer: diagnosis and treatment. 2009 (Last updated August 2017) [cited 16 November 2018]; Available from: https://www.nice.org.uk/guidance/cg81. 7. European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. EMA/CHMP/205/95 Rev.5. 2017. 8. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-600. Epub 09/22. 9. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. British journal of cancer. 2006;95(6):683-90. Epub 09/13.
This assessment is based on data submitted by the applicant company up to and including
15 February 2019.
*Agreement between the Association of the British Pharmaceutical Industry (ABPI) and the SMC on
guidelines for the release of company data into the public domain during a health technology
Medicine prices are those available at the time the papers were issued to SMC for consideration.
SMC is aware that for some hospital-only products national or local contracts may be in place for
comparator products that can significantly reduce the acquisition cost to Health Boards. These
contract prices are commercial in confidence and cannot be put in the public domain, including via
the SMC Detailed Advice Document. Area Drug and Therapeutics Committees and NHS Boards are
therefore asked to consider contract pricing when reviewing advice on medicines accepted by
SMC.
Patient access schemes: A patient access scheme is a scheme proposed by a pharmaceutical company in order to improve the cost-effectiveness of a medicine and enable patients to receive access to cost-effective innovative medicines. A Patient Access Scheme Assessment Group (PASAG), established under the auspices of NHS National Services Scotland reviews and advises NHSScotland on the feasibility of proposed schemes for implementation. The PASAG operates separately from SMC in order to maintain the integrity and independence of the assessment
process of the SMC. When SMC accepts a medicine for use in NHSScotland on the basis of a patient access scheme that has been considered feasible by PASAG, a set of guidance notes on the operation of the scheme will be circulated to Area Drug and Therapeutics Committees and NHS Boards prior to publication of SMC advice.
Advice context:
No part of this advice may be used without the whole of the advice being quoted in full.
This advice represents the view of the Scottish Medicines Consortium and was arrived at after
careful consideration and evaluation of the available evidence. It is provided to inform the
considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in
determining medicines for local use or local formulary inclusion. This advice does not override the
individual responsibility of health professionals to make decisions in the exercise of their clinical
judgement in the circumstances of the individual patient, in consultation with the patient and/or